Two Directors at Transocean Ltd sold 196,911 shares at 5.000USD. The significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Chop Continues; Nasdaq 100 Testing Major Resistance We maintain our near-term bullish outlook on the S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM), which has remained in place since 4/22/25, aside from one week (11/19/25-11/25/25) when we went to neutral. We will stay near-term bullish as long as crucial support levels of 6824 on SPX, $610 on QQQ, and $245 on IWM continue to hold. We see mild deterioration in market dynamics, which may provide a near-term headwind; still, MAG7 earning...
Transocean Ltd. Announces Fourth Quarter 2025 Earnings Release Date STEINHAUSEN, Switzerland, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) announced today that it will report earnings for the fourth quarter 2025 and issue a fleet status report on Thursday, February 19, 2026, after the close of trading on the New York Stock Exchange. The company will conduct a teleconference starting at 9 a.m. EST, 3 p.m. CET, on Friday, February 20, 2026. Individuals who wish to participate in the teleconference should dial approximately 15 minutes prior to the scheduled start time an...
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that George Ng, Chief Executive Officer, and Patrick Lin, Chief Business & Strategy Officer and Founder, will attend the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, California. During the conference, Mr. Ng and Mr. Lin will be available for one-on-o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Golub Capital BDC, Inc. (GBDC) and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 7 January 2026 in which we reassessed the appropriateness of the ratings in ...
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim analysis in its ongoing Phase 2 clinical study evaluating NGC-Cap, Processa’s proprietary combinatio...
Transocean Ltd. Announces Contract Award and Extension Totaling $168 Million STEINHAUSEN, Switzerland, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) (“Transocean”) today announced a contract award and an extension, respectively, for two of its drilling rigs. Together, the fixtures represent approximately $168 million of firm backlog. In Brazil, the Deepwater Mykonos was awarded a contract with bp. The estimated 302-day campaign is expected to begin in the third quarter of 2026 and contribute approximately $120 million in backlog, excluding additional services and compen...
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct formal interim analysis in early 2026 VERO BEACH, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today provided a clinical update on its ongoing Phase 2 study of NGC-Cap...
Transocean Ltd. Announces $130 Million Award for Ultra-Deepwater Drillship STEINHAUSEN, Switzerland, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) (“Transocean”) today announced the execution of a six-well contract in Australia with an undisclosed operator for the Deepwater Skyros. The estimated 320-day campaign is expected to commence in the first quarter of 2027 and contribute approximately $130 million in backlog, excluding compensation for mobilization and demobilization. The award includes priced options that, if fully exercised, could keep the drillship working in Au...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.